Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
26,85 EUR | +1,19 % | +2,40 % | +2,87 % |
Kurzporträt
- Produkte für die Erstversorgung (72,8%): Arzneimittel für die innere Medizin, Impfstoffe, Arzneimittel zur Vorbeugung und Behandlung von Covid-19, Virostatika, mRNA-basierte Produkte usw.;
- Spezialmedikamente (13,8%): Arzneimittel für die Immunologie, für Krankenhäuser und für die Behandlung seltener Krankheiten, entzündungshemmende Medikamente, usw;
- Onkologieprodukte (12,1%);
- Sonstige (1,3%).
Ende 2022 verfügte die Gruppe über mehr als 35 Produktionsstätten weltweit.
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (42,3%), Europa (21,9%) und Sonstige (35,8%).
Mitarbeiterzahl: 88 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Biopharma
97,8
%
| 98 988 | 98,7 % | 57 186 | 97,8 % | -42,23 % |
Other Business Activities
2,2
%
| 1 342 | 1,3 % | 1 310 | 2,2 % | -2,38 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
46,3
%
| 42 473 | 42,3 % | 27 088 | 46,3 % | -36,22 % |
Emerging Markets
20,5
%
| 20 097 | 20,0 % | 11 996 | 20,5 % | -40,31 % |
Developed Europe
19,9
%
| 21 982 | 21,9 % | 11 650 | 19,9 % | -47,00 % |
Developed Rest of World
7,3
%
| 7 752 | 7,7 % | 4 251 | 7,3 % | -45,16 % |
Japan
6,0
%
| 8 026 | 8,0 % | 3 510 | 6,0 % | -56,27 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 01.01.93 |
David Denton
DFI | Director of Finance/CFO | 59 | 02.05.22 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 01.07.19 |
Chief Tech/Sci/R&D Officer | - | 01.01.07 | |
Lidia Fonseca
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
Aida Habtezion
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.21 |
Rady Johnson
CMP | Compliance Officer | 63 | 01.01.94 |
Mikael Dolsten
CTO | Chief Tech/Sci/R&D Officer | 65 | 01.10.09 |
Maria Rivas
CTO | Chief Tech/Sci/R&D Officer | 60 | 01.09.22 |
Investor Relations Contact | - | 19.07.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 66 | 01.04.20 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 23.02.17 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 27.09.13 |
Suzanne Johnson
BRD | Director/Board Member | 66 | 01.09.07 |
Scott Gottlieb
BRD | Director/Board Member | 51 | 27.06.19 |
Jim Smith
BRD | Director/Board Member | 64 | 26.06.14 |
James Quincey
BRD | Director/Board Member | 59 | 27.02.20 |
Director/Board Member | 66 | 25.06.15 | |
Dan Littman
BRD | Director/Board Member | 71 | 05.03.18 |
Albert Bourla
CEO | Chief Executive Officer | 62 | 01.01.93 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 9 591 592 898 | 5 663 767 188 ( 59,05 %) | 3 925 000 000 ( 40,92 %) | 59,05 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
HALEON PLC 32,36% | 2 955 063 626 | 32,36% | 12 562 123 227 $ |
PFIZER LIMITED 63,92% | 29 243 042 | 63,92% | 1 490 712 025 $ |
27 349 211 | 15,06% | 1 150 581 307 $ | |
ARVINAS, INC. 5,06% | 3 457 815 | 5,06% | 109 266 954 $ |
ALLOGENE THERAPEUTICS, INC. 12,91% | 22 032 040 | 12,91% | 62 901 474 $ |
AKERO THERAPEUTICS, INC. 3,65% | 2 525 252 | 3,65% | 47 803 020 $ |
VALNEVA 6,86% | 9 549 761 | 6,86% | 34 513 409 $ |
PYXIS ONCOLOGY, INC. 12,10% | 7 032 770 | 12,10% | 30 240 911 $ |
PYXIS ONCOLOGY, INC. 4,96% | 1 272 214 | 4,96% | 20 355 424 $ |
4 690 431 | 5,19% | 17 636 021 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Wyeth Holdings LLC
Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. |
Chemicals: Agricultural
|
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. |
Pharmaceuticals: Major
|
Thiakis Ltd.
Thiakis Ltd. Pharmaceuticals: MajorHealth Technology Thiakis Ltd. develops hormone-based treatments for obesity and other metabolic diseases. It focuses to commercialize an effective anti-obesity treatment based on a peptide hormone called oxyntomodulin. The company was founded in 2004 by Steve Bloom and John Burt and is headquartered in Sandwich, the United Kingdom. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
| |
Pfizer Manufacturing Ireland Unlimited Co.
Pfizer Manufacturing Ireland Unlimited Co. Pharmaceuticals: MajorHealth Technology Pfizer Manufacturing Ireland manufactures and exports pharmaceutical products. It offers formulation and manufacture of human pharmaceuticals and animal health care products. Its Dublin plant manufactures sterile pharmaceutical products. The company was founded in 1969 and is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Wyeth Consumer Healthcare, Inc.
Wyeth Consumer Healthcare, Inc. Pharmaceuticals: MajorHealth Technology Wyeth Consumer Healthcare, Inc. discovers, develops and manufactures health care products. The company is headquartered in Mississauga, Canada. |
Pharmaceuticals: Major
|
Ferrosan ApS
Ferrosan ApS Pharmaceuticals: OtherHealth Technology Ferrosan ApS manufactures and sells pharmaceutical products. Its products include herbal medicine, natural remedies, food supplements, and medical devices. The company was founded by Niels Jacob Herman Weitzmann in 1920 and is headquartered in Ballerup, Denmark. |
Pharmaceuticals: Other
|
John Wyeth & Brother Ltd.
John Wyeth & Brother Ltd. Pharmaceuticals: MajorHealth Technology John Wyeth & Bros Ltd. manufactures pharmaceutical products. Its products include protein therapeutics, the rheumatoid arthritis treatment Enbrel, the influenza vaccines Begrivac, and Agrippal medications for depression, hemophilia, cancer and bacterial infections. The company was founded in 1960 by John Wyeth and is headquartered in Taplow, the United Kingdom. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+45,82 % | 765 Mrd. | |
+40,95 % | 632 Mrd. | |
-6,16 % | 354 Mrd. | |
+19,86 % | 331 Mrd. | |
+9,32 % | 299 Mrd. | |
+18,45 % | 248 Mrd. | |
+11,88 % | 216 Mrd. | |
-0,78 % | 219 Mrd. | |
+5,90 % | 164 Mrd. |
- Börse
- Aktien
- 852009 Aktie
- 852009 Aktie
- Unternehmen Pfizer, Inc.